With the high cost of new drugs to cure hepatitis C, ensuring that real-world outcomes are consistent with those seen in clinical trials is important, explained Gail Bridges, PharmD, of Accredo Health. She explained that Accredo ensured patients adhered to hepatitis C drugs in order to get the best outcomes through a disease- and drug-specific education program.
With the high cost of new drugs to cure hepatitis C, ensuring that real-world outcomes are consistent with those seen in clinical trials is important, explained Gail Bridges, PharmD, of Accredo Health. She explained that Accredo ensured patients adhered to hepatitis C drugs in order to get the best outcomes through a disease- and drug-specific education program.
Transcript
What impact do you think drug-specific education had on patients taking Harvoni or Viekira Pak for hepatitis C? Is the model translatable to other disease states?
As we're all aware, adherence is challenging in the real world. In our experience I think it takes an array of support tools to really help patients succeed on these therapies. In our study patients received care from specialty pharmacists and nurses who focused solely on hepatitis C.
So they received drug- and disease-specific education, as well as access to technology support, such as the Accredo Plus C adherence app, videos, they received proactive adherence coaching throughout their therapy. So all of these things contributed to, I think, the results that we saw in this study [that cure rates in the real-world were similar to those in clinical trials for patients taking Viekira Pak and Harvoni for hepatitis C].
I don't think there's one solution for all patients, but I think having a robust toolkit of these support methodologies, if you will, is important, so taht each patient can find the right tool that works for them.
With the high cost of hepatitis C drugs, what is the importance of determining the real-world outcomes and the fact that they are similar to clinical trial results?
We all are stewards of our healthcare resources, right? So we all have a role to play in ensuring judicious use of those resources. And any time there's such a large increase in cost, as we saw with the advent of the direct-acting antiviral era, we have to examine those real-world outcomes and make sure that those benefits are commensurate to that cost increase.
Historically, we've struggled a little bit in hepatitis C to really achieve real-world results that are on point with those seenn in clinical trials. So I think that it's exciting to see that we have data now to show that our patients, taking these medications in the specialty model can achieve those types of results that are consistent with those seen in clinical trials.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More